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Introduction
The segregation of sister chromatids to daughter cells must be 
orchestrated with cytokinesis. Mad2 is an essential mitotic 
checkpoint mediator that arrests cells in metaphase by inhibit-
ing the E3 ubiquitin ligase anaphase-promoting complex (APC) 
through the formation of an inactive complex with Cdc20 (Li   
et al., 1997; Fang et al., 1998) until bipolar spindle attachment 
is completed. Moreover, deregulated Mad2 induces cytokinesis 
failure at a high frequency. This has been attributed to chromo-
some segregation errors (Hernando et al., 2004; Sotillo et al., 
2007), but it is possible that Mad2 might function directly in   
orchestrating the mitotic checkpoint with cytokinesis.
A key player in cytokinesis is the chromosome passenger 
complex (CPC), which consists of Aurora B, INCENP, survivin, 
and borealin (for review see Ruchaud et al., 2007). Aurora B is 
a protein kinase that phosphorylates several components in-
volved in cytokinesis, and INCENP is a scaffold protein that   
activates Aurora B. Although the CPC localizes at centromeres 
in early mitosis, it relocates to the central spindle at the meta-
phase to anaphase transition (Cooke et al., 1987; Schumacher   
et al., 1998). This relocation requires mitotic kinesin-like protein 2 
(MKlp2), a kinesin essential for cytokinesis in mammalian cells 
(Hill et al., 2000; Gruneberg et al., 2004).
In this study, we have identified MKlp2 as a mitotic tar-
get of Mad2. We further demonstrate that controlling MKlp2 
by Mad2 is important for mediating proper mitotic progres-
sion and cytokinesis.
Results and discussion
MKlp2 was previously copurified with tandem affinity purifica-
tion (TAP)–wild type (wt)–Mad2, but not with the nonfunctional 
deletion mutant, by mass spectrometry analysis after TAP of 
HEK293 cell lysates expressing TAP-tagged Mad2 (Lee et al., 
2008). Indeed, endogenous MKlp2 was coimmunoprecipitated 
with Myc epitope–tagged Mad2, but not the nonfunctional mu-
tant of Myc-Mad2(C20), using HEK293 cells (Fig. 1 A, lanes 
1–3). Similarly, using HeLa (Fig. 1 A, lanes 4–6) and HEK293 
cells (Fig. 1 A, lanes 7–9), HA-tagged MKlp2 was coimmuno-
precipitated with Myc-Mad2 but not Myc-Mad2(C10), in 
which the minimal functional region was deleted (Luo et al., 
2000). Using a series of deletion mutants of MKlp2 (Fig. 1 B), 
we found that the C-terminal region of MKlp2 encompassing 
amino acids 871–880 was required for Mad2 binding. Similar 
results were obtained using HeLa cells (unpublished data). Mad1 
and Cdc20 possess similar Mad2-binding motifs that conform to 
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e identified the mitotic kinesin-like protein 2 
(MKlp2), a kinesin required for chromosome 
passenger  complex  (CPC)–mediated  cyto-
kinesis, as a target of the mitotic checkpoint protein Mad2. 
MKlp2 possesses a consensus Mad2-binding motif re-
quired for Mad2 binding. Mad2 prevents MKlp2 from 
loading onto the mitotic spindle, a prerequisite step for its 
function as a mitotic kinesin. Furthermore, Mad2 inhibits 
the ability of MKlp2 to relocate the CPC from centromeres, 
an  essential  step  to  promote  cytokinesis.  An  MKlp2   
mutant that is refractory to Mad2-mediated inhibition pre-
maturely translocates to the mitotic spindle and mislocal-
izes the CPC component Aurora B from the midbody of 
dividing cells. This correlates with an increased incidence 
of cytokinesis failure. Together, these findings reveal that 
MKlp2 is a novel mitotic target of Mad2 necessary for 
proper mitotic progression and cytokinesis.
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but not found in its Kinesin-6 family member, MKlp1 (Fig. 1 C;   
for  review  see  Verhey  and  Hammond,  2009).  Indeed,  an 
MKlp2  mutant  in  which  residues  871–874  were  replaced   
with alanine (MKlp2(871A4)) failed to bind Mad2 (Fig. 1 D). 
the consensus sequence (K/R)XXXXXP (, an aliphatic resi-
due; X: any residue; Luo et al., 2002; Sironi et al., 2002). Amino 
acid  residues  871–879  of  MKlp2  conform  to  this  consensus   
sequence, which is conserved from human to Xenopus laevis  
Figure 1.  MKlp2 is a novel binding partner of Mad2. (A, B, and D) Immunoblot analysis with the indicated antibodies, and 10% of the input is shown 
as total lysates. The positions of molecular mass markers (kilodaltons) are indicated. (A) Lysates of HEK293 cells (lanes 1–3) expressing the indicated 
Myc-Mad2 or HeLa (lanes 4–6) and HEK293 (lanes 7–9) cells coexpressing Myc-Mad2 with HA-MKlp2 were subjected to immunoprecipitation (IP) with 
antibodies to (-) Myc or HA. (B) Lysates of HEK293 cells expressing HA-MKlp2 or the indicated mutants were subjected to immunoprecipitation with 
antibodies to HA. (C) Structural motifs of MKlp2 and alignment of the putative Mad2-binding sequences of MKlp2 with those of human Cdc20 and Mad1 
in comparison with human MKlp1. The indicted sequences were aligned using ClustalW (www.ebi.ac.uk/clustalw). (D) Lysates of HEK293 cells express-
ing HA-MKlp2 or HA-MKlp2(871A4) were subjected to immunoprecipitation with antibodies to HA. (E) Autoradiography of in vitro–translated HA-MKlp2 
proteins (left) and precipitates of GST pull-down analysis performed with the indicated proteins and either GST-Mad2 or GST (right). 10% of the input for 
total in vitro–translated product is shown.1071 MKlp2 is a mitotic target of Mad2 • Lee et al.
Next, we investigated whether Mad2 also inhibits MKlp2 
binding the mitotic spindle. Because the levels of ectopically ex-
pressed HA-MKlp2 were typically higher than endogenous MKlp2 
by >10-fold (unpublished data), we coexpressed Myc-Mad2 with 
HA-MKlp2 in HeLa cells. Subsequently, cells were exposed to 
K858, an inhibitor of the mitotic kinesin Eg5 (Nakai et al., 2009), 
to induce the formation of monoasters, a proteasome inhibitor 
MG132 to maintain Cdk1 active by inhibiting cyclin B1 degrada-
tion, and paclitaxel to stabilize the spindles (Fig. 3 C). HA-MKlp2 
largely localized in the mitotic cytoplasm (Fig. 3 C, a), whereas 
HA-MKlp2(871A4) localized in the mitotic spindle (Fig. 3 C, b). 
Moreover, endogenous MKlp2 localized to the mitotic spindle 
in Mad2-depleted cells (Fig. 3 C, d), whereas it did not in control 
(Fig. 3 C, c), suggesting Mad2 inhibits MKlp2 loading onto the 
mitotic spindle.
As relocating the CPC by MKlp2 to the central spindle is 
negatively controlled by Cdk1 (Hümmer and Mayer, 2009), we 
determined whether Mad2 together with Cdk1 coordinately reg-
ulates this event. To address this issue, HeLa cells coexpressing 
HA-MKlp2 and Myc-Mad2 were forced to form monoasters 
(Fig. 3 C), and the localizations of Aurora B and INCENP were 
determined (Fig. 4 A). HA-MKlp2 localized in the mitotic cyto-
plasm, whereas Aurora B and INCENP showed punctate centro-
mere staining patterns (Fig. 4 A, a and d). In contrast, HA-MKlp2 
(871A4) localized to the mitotic spindle independent of Aurora B 
and INCENP (Fig. 4 A, b and e). However, when these cells 
were treated with a Cdk1 inhibitor purvalanol A, HA-MKlp2 
(871A4) relocated with Aurora B and INCENP to the mitotic 
spindle (Fig. 4 A, c and f), suggesting that loading MKlp2 onto the 
mitotic spindle is a temporally separated step from the MKlp2-
mediated relocation of the CPC, the event that Cdk1 negatively 
controls. Moreover, when HeLa cells were treated with paclitaxel 
to stabilize the mitotic spindle and to activate the mitotic check-
point, MKlp2 showed a staining pattern of the paclitaxel-stabilized 
mitotic spindle in Mad2-depleted cells but not in control (Fig. 4 B, 
a and b). Indeed, MKlp2 localized to the mitotic spindle in 
Mad2-depleted cells (Fig. 4 B, c). Furthermore, as determined 
with the centromere marker CREST, MKlp2 was not found with 
Aurora B localized at centromeres in control cells (Fig. 4 B, d).   
In contrast, MKlp2 colocalized with Aurora B and INCENP in 
Mad2-depleted  cells  independent  of  purvalanol  A  treatment 
(Fig. 4 B, f–h). Depleting Mad2 prematurely activates the 
APC
Cdc20 complex, which inactivates Cdk1 by degrading cyclin B1 
(for review see Musacchio and Salmon, 2007). Indeed, when 
Mad2-depleted cells were treated with MG132 to stabilize   
cyclin B1, Aurora B and INCENP were at centromeres, whereas 
MKlp2 showed the mitotic spindle staining patterns (Fig. 4 B, 
i–k). Together, these results suggest that endogenous Mad2 pre-
vents MKlp2 from loading onto the mitotic spindle when the 
mitotic checkpoint is active. Furthermore, this regulatory step is 
temporally separated from the Cdk1-mediated regulation of MKlp2 
on relocating the CPC.
To determine whether Mad2 inhibits MKlp2 loading onto 
the mitotic spindle without spindle damage, we treated control or 
Mad2-depleted HeLa cells with MG132 to keep Cdk1 active and 
subsequently extracted the soluble cytosolic proteins to directly 
visualize MKlp2 bound to the mitotic spindle. Indeed, depleting 
Furthermore, although in vitro–translated HA-MKlp2(wt) and   
HA-MKlp2(1–880) bound recombinant GST-Mad2, HA-MKlp2 
(1–870) and HA-MKlp2(871A4) failed to do so (Fig. 1 E). Thus, 
we conclude that MKlp2 is a direct binding partner of Mad2.
As the C-terminal region of MKlp1 does not have se-
quence homology with MKlp2 (Fig. 1 C), Myc-Mad2 bound 
GST-tagged MKlp2 but not GST-MKlp1 (Fig. 2 A). Further-
more, treating with the microtubule destabilizer nocodazole, 
which activates the mitotic checkpoint, increased the levels of 
Myc-Mad2 bound to GST-MKlp2 (Fig. 2 A) and the levels of 
endogenous MKlp2 bound to Mad2 using HeLa cells (Fig. 2 B). 
Because Mad2 is essential for the mitotic checkpoint, we exam-
ined whether formation of the Mad2–MKlp2 complex is regu-
lated  by  mitotic  checkpoint  signaling  by  depleting  Mad1  to 
inactivate Mad2 (Chen et al., 1998, 1999). To avoid the com-
plication of using nocodazole, which increased the levels of 
MKlp2, HeLa cells were released from the G1–S boundary to 
mitosis. Endogenous MKlp2 bound Mad2 in the absence of   
nocodazole, whereas depleting Mad1 decreased the interaction 
(Fig. 2 C). Likewise, inactivating the mitotic checkpoint by de-
pleting BubR1 decreased the levels of Mad2 bound to MKlp2, 
where the comparable levels of mitotic marker phospho–Histone 
H3 (p-Histone H3) were found (Fig. 2 D). Moreover, Mad2   
coprecipitated with MKlp2 in early mitotic lysates (Fig. 2 E), 
whereas Aurora B did so in late mitotic lysates (Gruneberg et al., 
2004; Hümmer and Mayer, 2009), suggesting that Mad2 binds 
MKlp2 in early mitosis and that the mitotic checkpoint also pro-
motes this complex formation. Notably, MKlp2 did not bind 
Mad1 (not depicted), and depleting MKlp2 had no effect on the 
levels of Mad2 bound to Mad1, Cdc20, and the APC (Fig. 2,   
F and G), suggesting that endogenous MKlp2 does not compete 
with the binding partners of Mad2.
As MKlp2 is a motor that relocates the CPC to the central 
spindle at the metaphase to anaphase transition (Gruneberg   
et al., 2004), the motorless MKlp2(500–890) failed to relocate 
Aurora B (Fig. S1). Given that the interaction of kinesins with 
microtubules is an important regulatory step (for review see 
Verhey and Hammond, 2009), we examined whether Mad2 
controls the microtubule-binding ability of MKlp2. We chose 
HeLa cells because of their suitability for immunofluorescence 
analysis over HEK293 cells. Overexpressed kinesins often show 
a filamentous staining pattern in interphase (Verhey et al., 1998). 
Although endogenous MKlp2, which is periodically expressed 
in mitosis (Hill et al., 2000), was not detected in the cytoplasm 
of interphasic cells, ectopically expressed HA-MKlp2 revealed 
such staining and colocalized with microtubules (Fig. 3 A). Fur-
thermore, when HEK293 cells expressing HA-MKlp2 with or 
without Myc-Mad2 were subjected to microtubule cosedimenta-
tion assay using taxol-stabilized microtubules (Fig. 3 B), 90%   
of HA-MKlp2 cosedimented with taxol-stabilized microtubules.   
In contrast, only 30% of HA-MKlp2 coexpressed with Myc-Mad2 
did so (Fig. 3 B, lanes 1–4), as quantified by phosphoimager 
analysis, suggesting that Mad2 inhibits the MKlp2-binding   
microtubule.  Notably,  HA-MKlp2(871A4)  cosedimented  with 
taxol-stabilized microtubules independent of Myc-Mad2 (Fig. 3 B, 
lanes 5–8), whereas it did not without taxol-stabilized micro-
tubules (Fig. 3 B, lanes 9 and 10).JCB • VOLUME 191 • NUMBER 6 • 2010   1072
Figure 2.  Mad2 binding to MKlp2 depends on the mitotic checkpoint. Immunoblot analysis with the indicated antibodies, and 10% of the input is shown 
as total lysates. The positions of molecular mass markers (kilodaltons) are indicated. (A) Lysates of HEK293 cells expressing GST-MKlp1, GST-MKlp2, or 
together with Myc-Mad2 were subjected to GST pull-down analysis. (B) HeLa cells growing asynchronously were treated with or without nocodazole for   
6 h. Cells were then lysed and subjected to immunoprecipitation (IP) with antibodies to Mad2. (C and D) HeLa cells transfected with control or Mad1 siRNAs 
or two different BubR1 siRNAs (#1 and #2; to ensure reproducibility) were synchronously released from the G1–S boundary. 7 h after release, cells were 
collected by mitotic shake off. Total cell lysates were subjected to immunoprecipitation analysis with the indicated antibodies. (E) Lysates of HeLa cells har-
vested at the indicated times after release from nocodazole block were subjected to immunoprecipitation with antibodies to MKlp2. (F and G) 48 h after 
transfection with control or MKlp2 siRNAs, HeLa cells were treated with nocodazole for 5 h and subjected to immunoprecipitation with antibodies to Mad1 
(F), Cdc27, a core component of the APC (G, lanes 4 and 5), or Cdc20 (G, lanes 7 and 8).1073 MKlp2 is a mitotic target of Mad2 • Lee et al.
HA-MKlp2(871A4)  with  Myc-Mad2  became  binucleated 
(Fig. 5 C) where HA-MKlp2(871A4) often localized at the entire 
mitotic cytoskeleton (Fig. 5 D). Furthermore, endogenous MKlp2 
and Aurora B specifically accumulated in the midbody of control 
cells undergoing cytokinesis (Fig. 5 E, a and c), whereas both 
proteins were also found at the mitotic cytoskeleton of Mad2-
depleted cells (Fig. 5 E, b and d), which were evident in Mad2-
depleted cells treated with paclitaxel.
Given that Mad2 inhibited MKlp2 binding of the mitotic 
spindles, we determined whether ectopically expressed Mad2 in-
hibits the ability of MKlp2 to relocate the CPC to the central 
spindle in dividing cells. Because overexpressing Mad2 arrested 
cells  in  metaphase,  HeLa  cells  expressing  Myc-Mad2  were   
exposed to purvalanol A for 2 h to induce exit from metaphase 
(Fig. 5 F). Determined by immunofluorescence analysis, MKlp2, 
Aurora B, and INCENP localized in the midbody of control cells 
Mad2 increased the levels of MKlp2 localized at the mitotic 
spindle compared with control (Fig. 5 A). Similar results were 
also observed in the absence of MG132 and Mad1-depleted HeLa 
cells (Fig. S2). Furthermore, ectopically expressed HA-MKlp2 
in metaphasic HeLa cells localized at the mitotic spindle (Fig. 5 B, 
a), whereas coexpressing Myc-Mad2 abolished it (Fig. 5 B, b). 
Although a Mad2-independnet effect of MKlp2(871A4) might 
exist, HA-MKlp2(871A4) localized at the mitotic spindle in all 
metaphasic cells expressing Myc-Mad2 (Fig. 5 B, c) indepen-
dent of MG132 treatment (Fig. 5 B, d). Moreover, inhibiting 
Cdk1 by purvalanol A failed to induce the mitotic spindle local-
ization of HA-MKlp2 in cells coexpressing Myc-Mad2 (Fig. 5 B, 
e and g), whereas HA-MKlp2(871A4) localized together with 
Aurora B and INCENP (Fig. 5 B, f and h), further suggesting 
that Mad2 inhibits MKlp2 binding the mitotic spindle inde-
pendent of Cdk1 activity. Notably, 20% of cells coexpressing 
Figure 3.  Mad2 inhibits MKlp2 loading onto the mitotic spindle. (A) HeLa cells expressing HA-MKlp2 were subjected to immunofluorescence analysis 
with the indicated antibodies. Inset shows enlarged view of the boxed area. (B) Lysates of HEK293 cells expressing the indicated HA-MKlp2 or Myc-Mad2 
proteins were supplemented with the taxol-stabilized microtubules (except lanes 9 and 10) and subjected to ultracentrifugation. The resulting supernatant 
(S) and pellet (P) fractions were then subjected to immunoblot analysis with the indicated antibodies. (C) HeLa cells were transfected with expression vectors 
encoding the indicated HA-MKlp2 together with Myc-Mad2 (a and b) or the indicated siRNAs (c and d). Cells were then treated with K858, MG132, and 
paclitaxel to form monoasters and were subjected to immunofluorescence analysis. HeLa cells (n > 100) were scored as having MKlp2 colocalized (blue 
bars) or not colocalized (red bars) with the mitotic spindle. Bars, 5 µm.JCB • VOLUME 191 • NUMBER 6 • 2010   1074
negatively regulates the ability of MKlp2 to relocate the CPC 
for cytokinesis.
In this study, we propose that MKlp2 is a mitotic target of 
Mad2 and provide several lines of evidence that the mitotic check-
point promotes complex formation between Mad2 and MKlp2 
(Fig. 2). MKlp2 bound Mad2 but not Mad1 in early mitosis, and 
(n > 50 each; Fig. 5 F, a, c, and e) but not in cells expressing 
Myc-Mad2 (n > 50 each; Fig. 5 F, b, d, and f), where MKlp2   
localized with Myc-Mad2 in the mitotic cytoplasm (Fig. 5 F, b). 
Determined by the punctate staining patterns, Aurora B and   
INCENP appeared to stay at centromeres of dividing cells ex-
pressing Myc-Mad2 (Fig. 5 F, d and f), suggesting that Mad2 
Figure 4.  Mad2 and Cdk1 coordinate the mitotic kinesin function of MKlp2 in a spatiotemporal manner. Immunofluorescence analysis using the indicated 
antibodies is shown. (A) HeLa cells were transfected with expression vectors encoding indicated HA-MKlp2 together with Myc-Mad2. Cells were then 
treated with K858, MG132, and paclitaxel to form monoasters. (B) HeLa cells transfected with control or Mad2 siRNAs were treated with paclitaxel. Where 
indicated, cells were treated with DMSO, purvalanol A, or MG132 before fixation. Bars, 5 µm.1075 MKlp2 is a mitotic target of Mad2 • Lee et al.
does not compete with the binding partners of Mad2. Notably, as 
kinetochore localization of Mad2 by Mad1 facilitates formation 
of the Mad2–Cdc20 complex (for review see Nasmyth, 2005), in-
hibiting MKlp2 by Mad2 might occur in a kinetochore-dependent 
manner, which remains to be tested. Furthermore, as relocating the 
CPC from centromeres is important to inhibit the mitotic check-
point at anaphase (Vázquez-Novelle and Petronczki, 2010), MKlp2 
might control the mitotic checkpoint by regulating the CPC.
the  mitotic  checkpoint  increased  the  levels  of  Mad2  bound  to 
MKlp2. Conversely, inactivating the mitotic checkpoint by deplet-
ing Mad1 or BubR1 decreased the levels of Mad2 bound to MKlp2. 
Depleting MKlp2 had no effect on the mitotic checkpoint induced by 
nocodazole treatment (unpublished data), suggesting that it does 
not regulate the Mad2-mediated checkpoint. Furthermore, deplet-
ing MKlp2 had no effect on the complex formations of Mad1–
Mad2 and Cdc20–Mad2, suggesting that endogenous MKlp2 
Figure  5.  Controlling  MKlp2  by  Mad2  is 
important for proper mitotic progression and 
cytokinesis.  (A,  B,  and  D–F)  Immunofluores-
cence analysis with the indicated antibodies   
is shown. (A) HeLa cells transfected with con-
trol or Mad2 siRNA for 48 h were treated 
with MG132 to arrest cells in metaphase and 
prepermeabilized before fixation (see Materi-
als and methods). (B and D) HeLa cells were 
transfected with vectors for HA-MKlp2 alone   
or together with Myc-Mad2. 24 h after trans-
fection, cells were treated with DMSO, purva-
lanol A, or MG132 before fixation. Arrows in   
B  indicate  HA-MKlp2(871A4)  prematurely 
localized  to  the  mitotic  spindle,  whereas   
arrows in D indicate the cleavage furrow of a 
dividing cell. (C) Mitotic HeLa cells expressing   
HA-MKlp2(wt)  (blue  bars)  or  HA-MKlp2(871A4) 
(red  bars)  together  with  Myc-Mad2  from  A   
were  scored  as  metaphasic  cells  having   
HA-MKlp2 in the mitotic cytoplasm or at the mi-
totic spindle and mitotic cells with cytokinesis 
defect. Means from three independent experi-
ments (n > 100 each) are shown. Error bars 
indicate mean ± SD. (E) HeLa cells were trans-
fected  with  control  or  Mad2  siRNAs.  48  h   
after transfection, cells were treated with DMSO 
(a and b) or paclitaxel (c and d) before fix-
ation. Arrows indicate the midbody. (F) HeLa 
cells were transfected with control or vector 
for Myc-Mad2. 24 h after transfection, cells 
were treated with purvalanol A for 2 h before 
fixation. (G) Schematic model. As cells prog-
ress from interphase to mitosis, Mad2 targets 
MKlp2 when the mitotic checkpoint is active. 
Upon  completion  of  the  mitotic  checkpoint, 
MKlp2 loads onto the mitotic spindle. Subse-
quently, Cdk1 is inactivated by the APC
Cdc20-
mediated degradation of cyclin B1 (B1), which 
permits MKlp2 to bind and relocate the CPC 
from centromeres to the central spindle to pro-
mote cytokinesis. Bars, 5 µm.JCB • VOLUME 191 • NUMBER 6 • 2010   1076
human Mad2 were described previously (Lee et al., 2008). Cytomegalovirus-
based vectors encoding human MKlp1 or MKlp2 were constructed by inser-
tion of PCR-derived cDNA (NCBI Protein database accession nos. AI910107.1 
and AQ196929.1 for MKlp1 and MKlp2, respectively) into pCAN1-HA or 
pDEST27 (Invitrogen) for GST-tagged proteins using the Gateway system 
(Invitrogen). Complementary DNAs for deletion mutants of MKlp2 were 
generated by PCR with appropriate primers and cloned into pCAN1-HA. 
Site-directed mutagenesis was performed with the use of a site-directed muta-
genesis system (GeneTailor; Invitrogen).
In vitro GST pull-down assay
Recombinant GST fusion proteins were expressed in Escherichia coli strain 
BL21(DE3)pLysS and purified with the use of glutathione agarose beads   
(GE Healthcare). HA-MKlp2 proteins were translated in vitro in the presence 
of a mixture of [
35S]cysteine and [
35S]methionine (PerkinElmer) with the use 
of a reticulocyte lysate system (Promega). GST and GST-tagged Mad2 were 
loaded onto glutathione agarose beads for 30 min at 4°C in the presence 
of NP-40 cell lysis buffer (50 mM Tris-HCl, pH 8.0, 120 mM NaCl, and 1% 
NP-40) containing 1 mM DTT, protease inhibitor mix (Complete Mini; 
Roche), and phosphatase inhibitor mixes I and II (Sigma-Aldrich). The beads 
were washed with the cell lysis buffer and incubated overnight at 4°C with 
in vitro–translated proteins. The beads were isolated and washed before the 
addition of SDS sample buffer.
Immunofluorescence analysis
Cells grown on poly-l-lysine–coated coverslips were fixed with 4% para-
formaldehyde for 10 min, permeabilized with 0.5% Triton X-100, and exposed 
to PBS containing 10% fetal bovine serum. For Fig. 5 A, cells were pre-
permeabilized with 0.005% digitonin in transport buffer (110 mM KOAc,   
20 mM Hepes, pH 7.3, 2 mM Mg(OAc)2, 0.5 mM EGTA, 2 mM DTT, and 
EDTA-free Complete Mini) for 4 min before fixation. They were incubated for 
at least 2 h with primary antibodies, including those to MKlp2 (B01 [Abnova] 
and A300-879A [Bethyl Laboratories, Inc.]), to Aurora B (H75), INCENP 
(H153), HA (Y11), Myc (9E10), and -tubulin (H235; Santa Cruz Biotechnol-
ogy, Inc.), to -tubulin (Sigma-Aldrich), or to CREST (ImmunoVision). Immune 
complexes were detected by incubation of the cells for 1 h with isotype- 
specific secondary antibodies coupled to Alexa Fluor 488 or Texas red (Invit-
rogen). Fixed slides were stained with Hoechst 33342 and mounted (mounting 
medium; Kirkegaard & Perry Laboratories, Inc.). Images for single optical 
sections of confocal microscopy were acquired at RT with a camera   
(AxioCam HRc; Carl Zeiss, Inc.) mounted on a microscope (Axiovert 100M; 
Carl Zeiss, Inc.) with a Plan Apochromat 63× 1.40 NA oil objective. Images 
were deconvoluted with image software (LSM 5; Carl Zeiss, Inc.), and con-
trast  enhancement  was  performed  using  Photoshop  software  (Element  8; 
Adobe). For Fig. 3 C (c and d), images were obtained using a laser-scanning 
microscope (LSM710; Carl Zeiss, Inc.) and deconvoluted with ZEN image 
software (2010; Carl Zeiss, Inc.).
Cell synchronization
A control nonsilencing siRNA and siRNAs specific for MKlp2 (SI02654064 
or SI03060015), Mad1 (SI00052808), Mad2 (SI02653847), or BubR1 
(SI00605010 or SI00605017, to ensure reproducibility) mRNAs were ob-
tained from QIAGEN. Cells were synchronized at the G1–S boundary by 
exposure to 2 mM thymidine for 16 h, incubation in fresh medium for 10 h 
(during which time they were transfected with 100 nM siRNAs with the use 
of Lipofectamine 2000), and exposure again to 2 mM thymidine for 14 h. 
The cells were subsequently washed, incubated in fresh medium, and har-
vested at the indicated times.
Immunoprecipitation and immunoblot analysis
For Fig. 2 (C and D), HeLa cells released synchronously from the G1–S 
boundary were harvested by mitotic shake off, and cell lysates were sub-
jected to immunoprecipitation with rabbit antibodies to Mad2 (FL205; Santa 
Cruz  Biotechnology,  Inc.)  and  MKlp2  (A300-878A;  Bethyl  Laboratories, 
Inc.), respectively. For Fig. 2 E, nocodazole-arrested HeLa cells that were 
collected by mitotic shake off were washed with PBS, released in fresh me-
dium, and harvested at the indicated times. For Fig. 2 (F and G), 48 h after 
siRNA transfections, cells were treated with nocodazole for 5 h before being 
lysed in NP-40 cell lysis buffer. Cell lysates were then subjected to immuno-
precipitation with antibodies to Mad1 (9B10), Cdc27 (C4), or Cdc20 
(H175) obtained from Santa Cruz Biotechnology, Inc. For transient transfec-
tion, HeLa or HEK293 cells were transfected with equal amounts of indicated 
expression vectors (2 µg each). About 24–48 h after transfections, cells were 
lysed in NP-40 cell lysis buffer and subjected to immunoprecipitation with   
2 µg agarose-conjugated antibodies to HA (Y11) or Myc (9E10; Santa Cruz 
Together  with  that  inhibiting  Cdk1  activity  promoted 
MKlp2 and CPC to the mitotic spindle (Hümmer and Mayer, 
2009), we propose that at least two temporally and biochemically 
separable  steps  are  involved  in  orchestrating  the  function  of 
MKlp2.  First,  Mad2  negatively  controls  the  step  of  loading 
MKlp2 onto the mitotic spindle independent of the CPC. Second, 
Cdk1 activity determines the timing of MKlp2 relocating the 
CPC. These results do not necessarily contradict that T59 phos-
phorylation of INCENP by Cdk1 controls the translocation of the 
CPC and MKlp2 to the midzone during the metaphase to ana-
phase transition. Instead, we report that the active mutant of 
MKlp2 constitutively bound the mitotic spindle independent of 
the CPC, suggesting that loading MKlp2 onto the mitotic spindle 
does not require the CPC in early mitosis. Completion of bipolar 
spindle attachment results in the termination of the mitotic check-
point. Thus, this two-step mechanism of regulating MKlp2 by 
Mad2 and Cdk1 might orchestrate timing of bipolar spindle   
attachment, which terminates the Mad2-mediated mitotic check-
point, allowing MKlp2 to load onto the mitotic spindle. Sub-
sequently, segregation of sister chromatids upon Cdk1 inactivation 
relocates the CPC by MKlp2 to the central spindle for cytokinesis 
(Fig. 5 G). Furthermore, as depleting Mad2 mislocalized MKlp2 
to the mitotic cytoskeleton, Mad2 might be a part of a mechanism 
controlling “free” MKlp2 in postmetaphase cells, suggesting a 
potential role of Mad2 in late mitotic phases.
We also report that Mad2 inhibits microtubule association 
of MKlp2 through the C-terminal region of MKlp2, which lo-
cates outside of its microtubule-binding motor domain. Although 
kinesins often function as dimers through their nonmotor regions, 
an excess amount of recombinant Mad2 did not compromise the 
self-multimerizing ability of MKlp2 (unpublished data). Instead, 
as folding the tail and motor domains of kinesins together is sug-
gested as a general mechanism for inhibiting kinesin motors (for 
review see Verhey and Hammond, 2009), Mad2 might keep 
MKlp2 in a folded inactive state in early mitosis. Furthermore, as 
the C-terminal region of MKlp2 is evolutionary conserved from 
Humans to Xenopus, the generality of mechanism controlling 
MKlp2 by Mad2 also warrants further investigation. Notably,   
although Mad2 did not bind MKlp1 (Fig. 2 A), Cdk1/cyclin B   
directly phosphorylates the motor domain of MKlp1 on an evolu-
tionary conserved site within a basic N-terminal region that 
inhibits its binding to microtubules (Mishima et al., 2004), 
suggesting a distinctive role of Mad2 in controlling MKlp2.
In summary, MKlp2 is an important mitotic target of Mad2 
that controls CPC-mediated cytokinesis. Mad2 is overexpressed   
in many human cancers, which is thought to be a direct cause of 
chromosome instability and tumorigenesis (Hernando et al., 2004; 
Sotillo et al., 2007), raising the possibility that deregulated Mad2 
causes cytokinesis failure by misregulating MKlp2 and the CPC, 
and so contributes to chromosome instability and tumorigenesis.
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Biotechnology, Inc.). For Fig. 2 A, 12 h after transfection, cells were treated 
with 200 ng/ml nocodazole or DMSO for 12 h and subjected to GST pull-
down analysis. For immunoblot analysis, antibodies to Mad2 (17D10 or 
FL205), Myc (9E10), HA (Y11 or F7), GST (B14), Mad1 (9B10), BubR1 
(H23) or Aurora B (H75) were obtained from Santa Cruz Biotechnology, 
Inc., antibody to -actin was obtained from Sigma-Aldrich, and antibody to 
MKlp2 was obtained from Bethyl Laboratories and Abnova. Immune com-
plexes were detected with the use of ECL reagents (GE Healthcare).
Microtubule-binding and mitotic spindle–binding assays
For Fig. 3 B, HEK293 cells expressing HA-MKlp2 or with Myc-Mad2 were 
lysed in NP-40 cell lysis buffer, and equal amounts of lysates were subjected 
to a microtubule-binding assay with the use of the Microtubule Binding Pro-
tein Spin-Down Assay kit (Cytoskeleton, Inc.). Cell lysates supplemented with 
taxol-stabilized microtubules were centrifuged at 40,000 rpm for 40 min at 
RT. After immunoblot analysis, each blot was quantified by phosphorimager 
using ImageQuant software (Molecular Dynamics). For Fig. 3 C, HeLa cells 
transfected with siRNAs were treated with 10 µM K858 and 10 µM MG132 
for 2 h. Cells were treated with10 µM paclitaxel for 30 min before fixation. 
For Figs. 3 C and 4 A, after transfection with vectors for Myc-Mad2 and   
HA-MKlp2, HeLa cells were treated with 10 µM K858 for 12 h and fixed for 
immunofluorescence analysis. Where indicated in Figs. 4 and 5 B, cells were 
treated with 10 µM purvalanol A for 30 min before fixation. For Fig. 5 A, 
cells were treated with 10 µM MG132 for 4 h. For Fig. 4 B and the panels 
indicated in Fig. 5 E, 48 h after siRNA transfections, cells were treated with 
10 µM paclitaxel for 2 h before fixation. For Fig. 5 F, 24 h after transfections, 
cells were treated with purvalanol A for 2 h before fixation.
Online supplemental material
Fig. S1 shows HeLa cells transfected with MKlp2 siRNA specific for the   
N terminus of MKlp2 mRNA (SI02654064; QIAGEN) to deplete endog-
enous MKlp2. 24 h after transfection, cells were transfected with pCAN1 
plasmid encoding the motorless HA-MKlp2(500–890) proteins, fixed, and 
subjected to immunofluorescence analysis with antibodies to HA (F7; Santa 
Cruz Biotechnology, Inc.) or Aurora B (H75; Santa Cruz Biotechnology, Inc.). 
Fig. S2 shows HeLa cells transfected with control, Mad1 (SI00052808), or 
Mad2 (SI02653847) siRNAs (QIAGEN). 48 h after transfection, cells 
were prepermeabilized with digitonin in transport buffer before fixation 
and subjected to immunofluorescence analysis using antibodies to -tubulin 
(Sigma-Aldrich) and MKlp2 (A300-879A; Bethyl Laboratories, Inc.). Online 
supplemental  material  is  available  at  http://www.jcb.org/cgi/content/ 
full/jcb.201003095/DC1.
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